Department of Neurology, People's Hospital of Deyang City, DeYang, China.
Department of Neurology, The Affiliated Hospital of Southwest Medical University, LuZhou, China.
Eur Neurol. 2021;84(1):38-42. doi: 10.1159/000512813. Epub 2021 Jan 21.
The aim is to observe the effects of argatroban injection and butylphthalide injection on blood flow rheology, clinical efficacy, and safety in patients with acute cerebral infarction.
344 patients with acute cerebral infarction within 48 h after admission were divided into treatment group and control group, with 172 cases in each group. The control group received routine treatment. The treatment group received argatroban injection 60 mg on the basis of the control group, intravenously guttae (ivgtt) was used for 2 days and then changed to argatroban injection 10 mg, ivgtt bid for 5 days, and the total course of treatment was 7 days. The neurological changes, activities of daily living, and the rheology indicators (fibrinogen [Fib], platelet aggregation rate [Pag], whole blood high shear viscosity [Whsv], hematocrit [Hct]) were compared between the 2 groups, clinical efficacy and adverse drug reactions.
After treatment, the total effective rates of the treatment group and the control group were 90.70% (156 /172 cases) and 74.41% (128 and 172 cases), respectively, and the difference was statistically significant (p < 0.05). After treatment, the National Institutes of Health Stroke Scale scores of the treatment group and the control group were (7.05 ± 1.97) and (8.30 ± 1.79), respectively, and the Barthel index was (68.02 ± 11.07) and (62.32 ± 11.46), respectively. The difference was statistically significant (p < 0.05). After treatment, the treatment group and the control group were (2.66 ± 0.22) g/L and (3.50 ± 0.22) g/L, respectively, and Pag were (0.68 ± 0.06)% and (0.81 ± 0.09)%, respectively, and Whsv was (6.44 ± 0.76) mPs/s and (6.87 ± 0.91) mPs/s, Hct were (8.19 ± 1.21)% and (10.44 ± 1.04)%, respectively, and the differences were statistically significant (p < 0.05). The incidence of adverse reactions in the treatment group and the control group was 6.97 and 5.81%, respectively, and the difference was not statistically significant (p > 0.05).
Argatroban injection is effective in the treatment of acute cerebral infarction, which can significantly improve the hemorheology of patients with good safety.
观察阿加曲班注射液与丁苯酞注射液对急性脑梗死患者血流流变学、临床疗效及安全性的影响。
将 344 例发病 48 h 内的急性脑梗死患者分为治疗组和对照组，每组 172 例。对照组给予常规治疗。治疗组在对照组基础上给予阿加曲班注射液 60 mg，静脉滴注（ivgtt）2 天，然后改为阿加曲班注射液 10 mg，bid ivgtt，连用 5 天，总疗程 7 天。比较两组患者的神经功能变化、日常生活活动能力及血液流变学指标（纤维蛋白原[Fib]、血小板聚集率[Pag]、全血高切黏度[Whsv]、红细胞压积[Hct]）、临床疗效及不良反应。
治疗后，治疗组总有效率为 90.70%（156/172 例），对照组为 74.41%（128/172 例），差异有统计学意义（p<0.05）。治疗后，治疗组和对照组的美国国立卫生研究院卒中量表评分分别为（7.05±1.97）和（8.30±1.79），Barthel 指数分别为（68.02±11.07）和（62.32±11.46），差异均有统计学意义（p<0.05）。治疗后，治疗组和对照组的纤维蛋白原分别为（2.66±0.22）g/L 和（3.50±0.22）g/L，血小板聚集率分别为（0.68±0.06）%和（0.81±0.09）%，全血高切黏度分别为（6.44±0.76）mPs/s 和（6.87±0.91）mPs/s，红细胞压积分别为（8.19±1.21）%和（10.44±1.04）%，差异均有统计学意义（p<0.05）。治疗组和对照组不良反应发生率分别为 6.97%和 5.81%，差异无统计学意义（p>0.05）。
阿加曲班注射液治疗急性脑梗死疗效确切，可明显改善患者的血液流变学，安全性良好。
